Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Secuado
- Development stage
- Approved
- Lead developer
- Hisamitsu Pharmaceutical
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
HP-3070 (Secuado) is a transdermal patch formulation of asenapine, a second-generation (atypical) antipsychotic. Developed by Hisamitsu Pharmaceutical and its subsidiary Noven Pharmaceuticals, it utilizes a proprietary Transdermal Drug Delivery System (TDDS) to provide continuous delivery of asenapine over a 24-hour period. It was the first transdermal antipsychotic approved by the FDA for the treatment of schizophrenia in adults. Asenapine's therapeutic effect is thought to be mediated through a combination of antagonist activity at dopamine D2 and serotonin 5-HT2A receptors. The transdermal route offers an alternative to sublingual administration, potentially improving adherence and avoiding the need for twice-daily dosing or food/drink restrictions associated with the sublingual form.
- Brand names
- Secuado
- Other names
- asenapine transdermal systemasenapine patch
02
Targets
ADRA2A (α2A)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)HRH1 (Histamine H1 Receptor)HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HTR7 (5-hydroxytryptamine receptor 7)
Beyond the preview
Go deeper on Secuado.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Secuado.